Infinity Pharmaceuticals, Inc. (INFI)
| Market Cap | 329.15M |
| Revenue (ttm) | 1.91M |
| Net Income (ttm) | -43.03M |
| Shares Out | 88.66M |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,988,894 |
| Open | 3.65 |
| Previous Close | 3.63 |
| Day's Range | 3.55 - 3.72 |
| 52-Week Range | 1.00 - 5.98 |
| Beta | 2.20 |
| Analysts | Buy |
| Price Target | 9.29 (+150.4%) |
| Est. Earnings Date | Nov 9, 2021 |
About INFI
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the d...
Financial Performance
In 2020, INFI's revenue was $1.72 million, a decrease of -43.62% compared to the previous year's $3.05 million. Losses were -$40.49 million, -13.95% less than in 2019.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for INFI stock is "Buy." The 12-month stock price forecast is 9.29, which is an increase of 150.40% from the latest price.
News
Infinity to Participate in Oppenheimer's Fall Healthcare Life Sciences and MedTech Summit and the 3rd Annual Macropha...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...
Infinity Pharmaceuticals Appoints Robert Ilaria, Jr., M.D., as Chief Medical Officer and Brian Schwartz, M.D.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macroph...
Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...
Hot Penny Stocks To Watch Making Big Moves This Week
Are these hot penny stocks on your watchlist right now? The post Hot Penny Stocks To Watch Making Big Moves This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Implied Volatility Surging for Infinity Pharmaceuticals (INFI) Stock Options
Investors need to pay close attention to Infinity Pharmaceuticals (INFI) stock based on the movements in the options market lately.
Best Biotech Penny Stocks For Your Monday Watchlist
With biotech penny stocks heating up, here are 3 you need to know about in August The post Best Biotech Penny Stocks For Your Monday Watchlist appeared first on Penny Stocks to Buy, Picks, News and Info...
Infinity Pharmaceuticals Reports Inducement Grants to Chief Scientific Officer under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially firs...
Why Infinity Pharmaceuticals Blasted 38% Higher Today
A big investment bank took a new and very bullish view on the stock.
5 Blazing Buy-Rated Stocks Under $10 With Gigantic Upside Potential
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
INFI Stock: Why Infinity Pharmaceuticals Is Soaring After Tuesday's Plunge
INFI stock is gaining nearly 50% today after two analysts said yesterday's data-driven drop created a buying opportunity. The post INFI Stock: Why Infinity Pharmaceuticals Is Soaring After Tuesday's Plu...
Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings
Infinity Pharmaceuticals Inc (NASDAQ: INFI) has issued data updates from two mid-stage trials for eganelisib, its oral immuno-oncology candidate. Data: 49 patients were enrolled in the MARIO-275 study d...
Infinity Pharmaceuticals (INFI) Reports Q2 Loss, Tops Revenue Estimates
Infinity (INFI) delivered earnings and revenue surprises of 0.00% and 30.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MAR...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class...
Infinity Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Company Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially firs...
Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Infinity Pharmaceuticals Hosting Webinar on MARIO-3 and MARIO-275 Phase 2 Trials
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...
Infinity to Present at The Keystone Symposia Precision Oncology Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...
Oppenheimer Has 5 Sizzling Biotech Stocks to Buy Now Trading Under $10
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates
Infinity (INFI) delivered earnings and revenue surprises of -7.14% and 0.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Infinity Pharmaceuticals: Q1 Earnings Insights
Shares of Infinity Pharmaceuticals (NASDAQ:INFI) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 21.05% year over year to ($0.15), which ...
Infinity Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Company Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially firs...
Infinity Announces the Date of Its First Quarter 2021 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...
Infinity to Present at New York Academy of Sciences' Frontiers in Cancer Immunotherapy 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...
Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Infinity to Present at the 7th Annual Truist Securities Life Sciences Summit
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...